Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 6/20 | 0.32 |
| ▸ | PPARD | Q03181 | 6/20 | 0.32 |
| ▸ | PPARA | Q07869 | 6/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801095 | 1.00 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL15545947 | 1.00 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL4223550 | 0.86 | FNTA (0.50) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL11045132 | 0.86 | FNTA (0.50) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL9289313 | 0.84 | FNTA (0.59) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL9289310 | 0.84 | FNTA (0.59) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL4331635 | 0.82 | FNTA (0.62) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL10478367 | 0.82 | FNTA (0.62) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL4788436 | 0.82 | FNTA (0.62) | FNTAFNTBTHRBPGGT1BCES2 | |
| SCHEMBL8372423 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-16 | — | — | US | disclosed |
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2874633-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | Relypsa, Inc. (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015244-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015240-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | PICALM, ORAI1, KCNN3 | HDAC3 2396/4885HDAC1 2212/4885HDAC2 2524/4885 |
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | SSB, PARG, HLA-DRB1 | HDAC3 692/4885HDAC1 252/4885HDAC2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.